Niculescu-Duvaz I - Search Results

1

Self-immolative nitrogen mustard prodrugs for suicide gene therapy.

Niculescu-Duvaz D, Niculescu-Duvaz I, Friedlos F, Martin J, Spooner R, Davies L, Marais R, Springer CJ. Niculescu-Duvaz D, et al. J Med Chem. 1998 Dec 17;41(26):5297-309. doi: 10.1021/jm980425k. J Med Chem. 1998. PMID: 9857097

2

Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.

Friedlos F, Davies L, Scanlon I, Ogilvie LM, Martin J, Stribbling SM, Spooner RA, Niculescu-Duvaz I, Marais R, Springer CJ. Friedlos F, et al. Cancer Res. 2002 Mar 15;62(6):1724-9. Cancer Res. 2002. PMID: 11912146

3

Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.

Niculescu-Duvaz D, Niculescu-Duvaz I, Friedlos F, Martin J, Lehouritis P, Marais R, Springer CJ. Niculescu-Duvaz D, et al. J Med Chem. 2003 Apr 24;46(9):1690-705. doi: 10.1021/jm020462i. J Med Chem. 2003. PMID: 12699387

4

Gene regulation in cancer gene therapy strategies.

Scanlon I, Lehouritis P, Niculescu-Duvaz I, Marais R, Springer CJ. Scanlon I, et al. Curr Med Chem. 2003 Oct;10(20):2175-84. doi: 10.2174/0929867033456837. Curr Med Chem. 2003. PMID: 12871091 Review.

5

Design of prodrugs for suicide gene therapy.

Niculescu-Duvaz D, Niculescu-Duvaz I, Springer CJ. Niculescu-Duvaz D, et al. Methods Mol Med. 2004;90:161-202. doi: 10.1385/1-59259-429-8:161. Methods Mol Med. 2004. PMID: 14657564 Review. No abstract available.

6

Introduction to the background, principles, and state of the art in suicide gene therapy.

Niculescu-Duvaz I, Springer CJ. Niculescu-Duvaz I, et al. Mol Biotechnol. 2005 May;30(1):71-88. doi: 10.1385/MB:30:1:071. Mol Biotechnol. 2005. PMID: 15805578 Review.

7

Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead.

Niculescu-Duvaz I, Roman E, Whittaker SR, Friedlos F, Kirk R, Scanlon IJ, Davies LC, Niculescu-Duvaz D, Marais R, Springer CJ. Niculescu-Duvaz I, et al. J Med Chem. 2006 Jan 12;49(1):407-16. doi: 10.1021/jm050983g. J Med Chem. 2006. PMID: 16392826

8

Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold.

Niculescu-Duvaz I, Roman E, Whittaker SR, Friedlos F, Kirk R, Scanlon IJ, Davies LC, Niculescu-Duvaz D, Marais R, Springer CJ. Niculescu-Duvaz I, et al. J Med Chem. 2008 Jun 12;51(11):3261-74. doi: 10.1021/jm070776b. Epub 2008 May 13. J Med Chem. 2008. PMID: 18473434

9

Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF).

Niculescu-Duvaz D, Gaulon C, Dijkstra HP, Niculescu-Duvaz I, Zambon A, Ménard D, Suijkerbuijk BM, Nourry A, Davies L, Manne H, Friedlos F, Ogilvie L, Hedley D, Whittaker S, Kirk R, Gill A, Taylor RD, Raynaud FI, Moreno-Farre J, Marais R, Springer CJ. Niculescu-Duvaz D, et al. J Med Chem. 2009 Apr 23;52(8):2255-64. doi: 10.1021/jm801509w. J Med Chem. 2009. PMID: 19323560

10

Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.

Ménard D, Niculescu-Duvaz I, Dijkstra HP, Niculescu-Duvaz D, Suijkerbuijk BM, Zambon A, Nourry A, Roman E, Davies L, Manne HA, Friedlos F, Kirk R, Whittaker S, Gill A, Taylor RD, Marais R, Springer CJ. Ménard D, et al. J Med Chem. 2009 Jul 9;52(13):3881-91. doi: 10.1021/jm900242c. J Med Chem. 2009. PMID: 19473026

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

74 results

Search Page